- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 611168-24-2] Glycerol phenylbutyrate
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-B2087 |
| Brand: | MCE |
| CAS: | 611168-24-2 |
Overview
| MDL | MFCD28016960 |
|---|---|
| Molecular Weight | 530.65 |
| Molecular Formula | C33H38O6 |
| SMILES | O=C(CCCC1=CC=CC=C1)OC(COC(CCCC2=CC=CC=C2)=O)COC(CCCC3=CC=CC=C3)=O |
Summary
IC50 & Target
σ2 receptor [1] .
In Vivo
Glycerol phenylbutyrate (GPB) has the potential for the treatment of hyperammonemia. Glycerol phenylbutyrate (GPB) may have therapeutic potential in additional conditions such as chronic hepatic encephalopathy or other inherited metabolic disorders [1] [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT05019417 | Kaplan Medical Center|Weizmann Institute of Science |
Monocarboxylate Transporter 8 Deficiency
|
June 30, 2021 | Phase 2|Phase 3 |
| NCT00977600 | Horizon Pharma Ireland, Ltd., Dublin Ireland|Ucyclyd Pharma, Inc. |
Healthy
|
March 2005 | Phase 1 |
| NCT01949766 | University of Pittsburgh |
Byler Disease
|
||
| NCT00551200 | Horizon Pharma Ireland, Ltd., Dublin Ireland |
Urea Cycle Disorders
|
October 2007 | Phase 2 |
| NCT02046434 | University of Colorado, Denver |
Parkinson´s Disease
|
January 2014 | Phase 1 |
| NCT01257737 | Horizon Therapeutics, LLC|Horizon Pharma Ireland, Ltd., Dublin Ireland |
Urea Cycle Disorders
|
October 4, 2010 | Phase 4 |
| NCT01347073 | Horizon Pharma Ireland, Ltd., Dublin Ireland |
Urea Cycle Disorders
|
July 2011 | Phase 3 |
| NCT04937062 | Weill Medical College of Cornell University|Children´s Hospital Colorado|SLC6A1 Connect|STXBP1 Foundation|Clara Inspired|University of Pennsylvania Orphan Disease Center|Horizon Therapeutics |
STXBP1 Encephalopathy With Epilepsy, SLC6A1 Neurodevelopmental Disorder
|
March 1, 2021 | Early Phase 1 |
| NCT00986895 | Horizon Pharma Ireland, Ltd., Dublin Ireland|Ucyclyd Pharma, Inc. |
Hepatic Encephalopathy|Urea Cycle Disorders
|
September 2006 | Phase 1 |
| NCT00947297 | Horizon Pharma Ireland, Ltd., Dublin Ireland |
Urea Cycle Disorders
|
November 2009 | Phase 3 |
| NCT00947544 | Horizon Pharma Ireland, Ltd., Dublin Ireland |
Urea Cycle Disorders
|
March 2010 | Phase 2 |
| NCT00992459 | Horizon Pharma Ireland, Ltd., Dublin Ireland |
Urea Cycle Disorders
|
October 2009 | Phase 3 |
| NCT00999167 | Horizon Pharma Ireland, Ltd., Dublin Ireland |
Cirrhosis|Hepatic Encephalopathy
|
December 2009 | Phase 2 |
| NCT01135680 | Horizon Pharma Ireland, Ltd., Dublin Ireland |
Drug Toxicity
|
May 2010 | Phase 1 |
Appearance
Oil
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Pure form | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : ≥ 150 mg/mL ( 282.67 mM )
Ethanol : 50 mg/mL ( 94.22 mM ; Need ultrasonic)
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.8845 mL | 9.4224 mL | 18.8448 mL |
| 5 mM | 0.3769 mL | 1.8845 mL | 3.7690 mL |
| 10 mM | 0.1884 mL | 0.9422 mL | 1.8845 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.25 mg/mL (4.24 mM); Clear solution
References
- [1] Rescifina A, et al. Development of a Sigma-2 Receptor affinity filter through a Monte Carlo based QSAR analysis. Eur J Pharm Sci. 2017 Aug 30;106:94-101.
- [2] Oishi K, et al. Glycerol phenylbutyrate for the chronic management of urea cycle disorders. Expert Rev Endocrinol Metab. 2014 Sep;9(5):427-434.
Synonyms
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.